Announcement of the Convening of the General Meeting in Munich/Germany on 21/05/2010 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
(Thomson Reuters ONE) -
MorphoSys AG / Announcement of the Convening of the General Meeting in Munich/Germany on 21/05/2010 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
MorphoSys AG
Martinsried/Planegg
Wertpapierkennnummer 663200
ISIN:DE0006632003
Invitation to the Annual Shareholders' Meeting 2010
We hereby invite the shareholders of our Company to the Annual Shareholders'
Meeting which is taking place on Friday, May 21, 2010 at 10:30 a.m., in the
Conference Centre Munich, Hanns-Seidel-Stiftung, Lazarettstraße 33, 80636
Munich.
Agenda
1. Presentation of the confirmed annual financial statements as of December
31, 2009, the management report together with the consolidated financial
statements, the consolidated management report and the report of the
Supervisory Board for the business year 2009 and the statement of the Board
of Management to the items pursuant to § § 289 para. 4, 315 para. 4 HGB
2. Formal approval on behalf of the Board of Management
3. Formal approval on behalf of the Supervisory Board
4. Appointment of the auditors for the business year 2010
5. Resolution on the approval of the remuneration scheme of Members of the
Board of Management
6. Resolution on the authorization to purchase and use treasury stock and on
the exclusion of subscription rights
7. Resolution on amendments of the articles of association in accordance with
the Act Implementing the Shareholders' Rights Directive (ARUG)
8. Partial deletion of the conditional capital 2003-II, amendment of the
Articles
9. Compensation of the Supervisory Board
Please find the full text of the announcement here:
http://www.morphosys.com/agm
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies
for therapeutic, diagnostic and research applications. The Company's HuCAL
technology is one of the most powerful methods available for generating fully
human antibodies. By successfully applying this and other proprietary
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human health-care.
Through its alliances with some of the world's leading pharmaceutical companies,
MorphoSys has created a pipeline of more than 60 drug candidates. The Company is
expanding its drug pipeline by adding new partnered programs, and by building a
portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio,
the Company is focused on the areas of oncology and inflammation. Its most
advanced program MOR103, a first-in-class, fully human antibody against GM-CSF,
is currently tested in a Phase Ib/IIa trial in rheumatoid arthritis patients.
Via its business unit AbD Serotec, MorphoSys is expanding the reach of its
technologies in the diagnostics and research markets. MorphoSys is headquartered
in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol
"MOR". For further information, visithttp://www.morphosys.com/
[HUG#1401873]
--- End of Message ---
MorphoSys AG
Lena-Christ-Str. 48 Martinsried / München Germany
WKN: 663200;ISIN: DE0006632003;Index:TecDAX,TECH All Share,HDAX,Prime All Share,CDAX,MIDCAP;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 09.04.2010 - 10:30 Uhr
Sprache: Deutsch
News-ID 1012671
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 95 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Announcement of the Convening of the General Meeting in Munich/Germany on 21/05/2010 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution
"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
